The natural interferon-α producing cells in systemic lupus erythematosus

Human Immunology

Volumn 63, Issue 12, 2002, Pages 1181-1193

  Rönnblom, Lars ^a   Alm, Gunnar V ^b  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Dendritic cells; Interferon alpha; Lupus; SLE; Type I interferon

Indexed keywords

ALPHA INTERFERON; CHLOROQUINE; SINGLE STRANDED DNA;

ANTIGEN PRESENTING CELL; ARTICLE; AUTOIMMUNITY; DENDRITIC CELL; HUMAN; IMMUNE COMPLEX DISEASE; IMMUNE SYSTEM; IMMUNOREGULATION; INHIBITION KINETICS; INTERFERON PRODUCTION; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGULATORY MECHANISM; SYSTEMIC LUPUS ERYTHEMATOSUS; TARGET CELL;

AUTOANTIBODIES; DENDRITIC CELLS; HUMANS; INTERFERON TYPE I; INTERFERON-ALPHA; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 0036927108     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0198-8859(02)00757-7     Document Type: Article

References (105)

1. Isaacs A, Lindenmann J: Virus interference. I. The interferon. Proc R Soc B 147:258, 1957.
2. Farrar MA, Schreiber RD: The molecular cell biology of interferon-gamma and its receptor. Annu Rev Immunol 11:571, 1993.
3. Pestka S: The human interferon α species and receptors. Biopolymers 55:254, 2000.
4. Billiau A: Interferon-gamma: Biology and role in pathogenesis. Adv Immunol 62:61, 1996.
5. Biron CA, Nguyen KB, Pien GC: Innate immune responses to LCMV infections: Natural killer cells and cytokines. Curr Top Microbiol Immunol 263:7, 2002.
6. Biron CA: Initial and innate responses to viral infections-pattern setting in immunity or disease. Curr Opin Microbiol 2:374, 1999.
7. Biron CA: Interferons α and β as immune regulators - A new look. Immunity 14:661, 2001.
8. Belardelli F, Ferrantini M: Cytokines as a link between innate and adaptive antitumor immunity. Trends Immunol 23:201, 2002.
9. Bogdan C: The function of type I interferons in antimicrobial immunity. Curr Opin Immunol 12:419, 2000.
10. Belardelli F: Role of interferons and other cytokines in the regulation of the immune response. APMIS 103:161, 1995.
11. Belardelli F, Gresser I: The neglected role of type I interferon in the T-cell response: Implications for its clinical use. Immunol Today 17:369, 1996.
12. Colonna M, Krug A, Cella M: Interferon-producing cells: On the front line in immune responses against pathogens. Curr Opin Immunol 14:373, 2002.
13. Shortman K, Liu YJ: Mouse and human dendritic cell subtypes. Nature Rev Immunol 2:151, 2002.
14. Liu YJ, Kanzler H, Soumelis V, Gilliet M: Dendritic cell lineage, plasticity and cross-regulation. Nat Immunol 2:585, 2001.
15. Brassard DL, Grace MJ, Bordens RW: Interferon-α as an immunotherapeutic protein. J Leukoc Biol 71:565, 2002.
16. Nguyen MH, Wright TL: Therapeutic advances in the management of hepatitis B and hepatitis C. Curr Opin Infect Dis 14:593, 2001.
17. Öberg K: Interferon in the management of neuroendocrine GEP-tumors: A review. Digestion 62(suppl 1):92, 2000.
18. Burman P, Karlsson FA, Öberg K, Aim G: Autoimmune thyroid disease in interferon-treated patients. Lancet ii:100, 1985.
19. Abdi EA, Brien W, Venner PM: Auto-immune thrombocytopenia related to interferon therapy. Scand J Haematol 36:515, 1986.
20. Rönnblom LE, Alm GV, Öberg KE: Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med 115:178, 1991.
21. Ioannou Y, Isenberg DA: Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum 43:1431, 2000.
22. Raanani P, Ben-Bassat I: Immune-mediated complications during interferon therapy in hematological patients. Acta Haematol 107:133, 2002.
23. Rönnblom LE, Alm GV, Öberg KE: Possible induction of systemic lupus erythematosus by interferon-α treatment in a patient with a malignant carcinoid tumour. J Intern Med 227:207, 1990.
24. Kälkner KM, Rönnblom L, Karlsson Parra AK, Bengtsson M, Olsson Y, Oberg K: Antibodies against doublestranded DNA and development of polymyositis during treatment with interferon. Q J M 91:393, 1998.
25. Akbar AN, Lord JM, Salmon M: IFN-α and IFN-β: a link between immune memory and chronic inflammation. Immunol Today 21:337, 2000.
26. , Le Bon A, Schiavoni G, D'Agostino G, Gresser I, Belardelli F, Tough DF: Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14:461, 2001.
27. Ludewig B, Junt T, Hengartner H, Zinkernagel RM: Dendritic cells in autoimmune diseases. Curr Opin Immunol 13:657, 2001.
28. Sinigaglia F, D'Ambrosio D, Rogge L: Type I interferons and the Th1/Th2 paradigm. Dev Comp Immunol 23:657, 1999.
29. Ruuth K, Carlsson L, Hallberg B, Lundgren E: Interferon-α promotes survival of human primary B-lymphocytes via phosphatidylinositol 3-kinase. Biochem Biophys Res Commun 284:583, 2001.
30. Braun D, Caramalho I, Demengeot J: IFN-α/β enhances BCR-dependent B cell responses. Int Immunol 14:411, 2002.
31. Mattei F, Schiavoni G, Belardelli F, Tough DF: IL-15 is expressed by dendritic cells in response to type I IFN, double-stranded RNA, or lipopolysaccharide and promotes dendritic cell activation. J Immunol 167:1179, 2001.
32. Zhang X, Sun S, Hwang I, Tough DF, Sprent J: Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. Immunity 8:591, 1998.
33. Stahl-Hallengren C, Jonsen A, Nived O, Sturfelt G: Incidence studies of systemic lupus erythematosus in Southern Sweden: Increasing age, decreasing frequency of renal manifestations and good prognosis. J Rheumatol 27:685, 2000.
34. Wallace DJ, Hahn B: Dubois' Lupus Erythematosus. Baltimore: Williams and Wilkins, 1997.
35. Lahita RG: Systemic Lupus Erythematosus. New York: Academic Press, 1999.
36. Fritzler MJ: Clinical relevance of autoantibodies in systemic rheumatic diseases. Mol Biol Rep 23:133, 1996.
37. Preble OT, Black RJ, Friedman RM, Klippel JH, Vilcek J: Systemic lupus erythematosus: Presence in human serum of an unusual acid-labile leukocyte interferon. Science 216:429, 1982.
38. Strannegård O, Hermodsson S, Westberg G: Interferon and natural killer cells in systemic lupus erythematosus. Clin Exp Immunol 50:246, 1982.
39. Ytterberg SR, Schnitzer TJ: Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum 25:401, 1982.
40. Bengtsson AA, Sturfelt G, Truedsson L, Blomberg J, Alm G, Vallin H, Rönnblom L: Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity, but not with antiretroviral antibodies. Lupus 9:664, 2000.
41. Kanayama Y, Kim T, Inariba H, Negoro N, Okamura M, Takeda T, Inoue T: Possible involvement of interferon alfa in the pathogenesis of fever in systemic lupus erythematosus. Ann Rheum Dis 48:861, 1989.
42. von Wussow P, Jakschies D, Hochkeppel H, Horisberger M, Hartung K, Deicher H: MX homologous protein in mononuclear cells from patients with systemic lupus erythematosus. Arthritis Rheum 32:914, 1989.
43. Rönnblom L, Ramstedt U, Alm GV: Properties of human natural interferon-producing cells stimulated by tumor cell lines. Eur J Immunol 13:471, 1983.
44. Gobl AE, Funa K, Alm GV: Different induction patterns of mRNA for IFN-α and -β in human mononuclear leukocytes after in vitro stimulation with herpes simplex virus-infected fibroblasts and Sendai virus. J Immunol 140:3605, 1988.
45. Kadowaki N, Antonenko S, Lau JY, Liu YJ: Natural interferon α/β-producing cells link innate and adaptive immunity. J Exp Med 192:219, 2000.
46. Fitzgerald-Bocarsly P: Human natural interferon-α producing cells. Pharmacol Ther 60:39, 1993.
47. Svensson H, Johannisson A, Nikkilä T, Alm GV, Cederblad B: The cell surface phenotype of human natural interferon-α producing cells as determined by flow cytometry. Scand J Immunol 44:164, 1996.
48. O'Doherty U, Peng M, Gezelter S, Swiggard WJ, Betjes M, Bhardwaj N, Steinman RM: Human blood contains two subsets of dendritic cells, one immunologically mature and the other immature. Immunology 82:487, 1994.
49. Olweus J, BitMansour A, Warnke R, Thompson PA, Carballido J, Picker LJ, Lund-Johansen F: Dendritic cell ontogeny: A human dendritic cell lineage of myeloid origin. Proc Natl Acad Sci USA 94:12551, 1997.
50. Grouard G, Rissoan MC, Filgueira L, Durand I, Banchereau J, Liu YJ: The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. J Exp Med 185:1101, 1997.
51. Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, Ho S, Antonenko S, Liu YJ: The nature of the principal type 1 interferon-producing cells in human blood. Science 284:1835, 1999.
52. Dzionek A, Fuchs A, Schmidt P, Cremer S, Zysk M, Miltenyi S, Buck DW, Schmitz J: BDCA-2, BDCA-3, and BDCA-4: Three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol 165:6037, 2000.
53. Dzionek A, Sohma Y, Nagafune J, Cella M, Colonna M, Facchetti F, Günther G, Johnston I, Lanzavecchia A, Nagasaka T, Okada T, Winkels G, Yamamoto T, Zysk M, Yamaguchi Y, Schmitz J: BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen-capture and is a potent inhibitor of interferon-α/β induction. J Exp Med 194:1823, 2001.
54. Svensson H, Cederblad B, Lindahl M, Alm G: Stimulation of natural interferon-α/β-producing cells by staphylococcus aureus. J Interferon Cytokine Res 16:7, 1996.
55. Cederblad B, Blomberg S, Vallin H, Perers A, Alm GV, Rönnblom L: Patients with systemic lupus erythematosus have reduced numbers of circulating natural interferon-α/β-producing cells. J Autoimmun 11:465, 1998.
56. Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J: Induction of dendritic cell differentiation by IFN-α in systemic lupus erythematosus. Science 294:1540, 2001.
57. Blomberg S, Eloranta ML, Cederblad B, Nordlin K, Alm GV, Rönnblom L: Presence of cutaneous interferon-α producing cells in patients with systemic lupus erythematosus. Lupus 10:484, 2001.
58. Farkas L, Beiske K, Lund-Johansen F, Brandtzaeg P, Jahnsen FL: Plasmacytoid dendritic cells (natural interferon-α/β-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol 159:237, 2001.
59. Cella M, Jarrossay D, Facchetti F, Alebardi O, Nakajima H, Lanzavecchia A, Colonna M: Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med 5:919, 1999.
60. Riffault S, Eloranta M-L, Carrat C, Sandberg K, Charley B, Alm G: Herpes simplex virus induced appearance of IFN-α/β producing cells and partially IFN-α/β dependent accumulation of leukocytes in murine regional lymph nodes. J Interferon Cytokine Res 16:1007, 1996.
61. Artursson K, Lindersson M, Varela N, Scheynius A, Alm GV: Interferon-α production and tissue localization of interferon-α/β producing cells after intradermal administration of Aujeszky's disease virus-infected cells in pigs. Scand J Immunol 41:121, 1995.
62. Vallin H, Blomberg S, Alm GV, Cederblad B, Rönnblom L: Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon-alpha (IFN-α) production acting on leucocytes resembling immature dendritic cells. Clin Exp Immunol 115:196, 1999.
63. Vallin H, Perers A, Alm GV, Rönnblom L: Anti-doublestranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-α inducer in systemic lupus erythematosus. J Immunol 163:6306, 1999.
64. Krieg AM: CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20:709, 2002.
65. Magnusson M, Magnusson S, Vallin H, Rönnblom L, Alm GV: Importance of CpG dinucleotides in activation of natural IFN-α-producing cells by a lupus-related oligodeoxynucleotide. Scand J Immunol 54:543, 2001.
66. Båve U, Alm GV, Rönnblom L: The combination of apoptotic U937 cells and lupus IgG is a potent IFN-α inducer. J Immunol 165:3519, 2000.
67. Båve U, Vallin H, Alm GV, Rönnblom L: Activation of natural interferon-α producing cells by apoptotic U937 cells combined with lupus IgG and its regulation by cytokines. J Autoimmun 17:71, 2001.
68. Davies KA, Robson MG, Peters AM, Norsworthy P, Nash JT, Walport MJ: Defective Fc-dependent processing of immune complexes in patients with systemic lupus erythematosus. Arthritis Rheum 46:1028, 2002.
69. Herrmann M, Voll RE, Kalden JR: Etiopathogenesis of systemic lupus erythematosus. Immunol Today 21:424, 2000.
70. Wagner H: Interactions between bacterial CpG-DNA and TLR9 bridge innate and adaptive immunity. Curr Opin Microbiol 5:62, 2002.
71. Krug A, Rothenfusser S, Hornung V, Jahrsdorfer B, Blackwell S, Ballas ZK, Endres S, Krieg AM, Hartmann G: Identification of CpG oligonucleotide sequences with high induction of IFN-α/β in plasmacytoid dendritic cells. Eur J Immunol 31:2154, 2001.
72. Krug A, Towarowski A, Britsch S, Rothenfusser S, Hornung V, Bals R, Giese T, Engelmann H, Endres S, Krieg AM, Hartmann G: Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol 31:3026, 2001.
73. Batteux F, Palmer P, Daeron M, Weill B, Lebon P: FcgammaRII (CD32)-dependent induction of interferonalpha by serum from patients with lupus erythematosus. Eur Cytokine Netw 10:509, 1999.
74. Dijstelbloem HM, van de Winkel JG, Kallenberg CG: Inflammation in autoimmunity: receptors for IgG revisited. Trends Immunol 22:510, 2001.
75. Fossati G, Bucknall RC, Edwards SW: Fcgamma receptors in autoimmune diseases. Eur J Clin Invest 31:821, 2001.
76. Dhodapkar KM, Krasovsky J, Williamson B, Dhodapkar MV: Antitumor monoclonal antibodies enhance crosspresentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J Exp Med 195:125, 2002.
77. Cella M, Facchetti F, Lanzavecchia A, Colonna M: Plasmacytoid dendritic cells activated by influenza virus and CD40L drive a potent Thl polarization. Nature Immunol 1:305, 2000.
78. Cederblad B, Gobl AE, Alm GV: The induction of interferon-α and interferon-β mRNA in human natural interferon-producing blood leukocytes requires de novo protein synthesis. J Interferon Res 11:371, 1991.
79. Cederblad B, Alm GV: Interferons and the colony-stimulating factors IL-3 and GM-CSF enhance the IFN-α response in human blood leucocytes induced by herpes simplex virus. Scand J Immunol 34:549, 1991.
80. Levy DE: Whence interferon? Variety in the production of interferon in response to viral infection. J Exp Med 195:F15, 2002.
81. Barnes B, Lubyova B, Pitha PM: Review: On the role of IRF in host defense. J Interferon Cytokine Res 22:59, 2002.
82. Payvandi F, Amrute S, Fitzgerald-Bocarsly P: Exogenous and endogenous IL-10 regulate IFN-α production by peripheral blood mononuclear cells in response to viral stimulation. J Immunol 160:5861, 1998.
83. Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN: Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: Findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 43:2383, 2000.
84. Shakoor N, Michalska M, Harris CA, Block JA: Druginduced systemic lupus erythematosus associated with etanercept therapy. Lancet 359:579, 2002.
85. Rissoan MC, Soumelis V, Kadowaki N, Grouard G, Briere F, de Waal Malefyt R, Liu YJ: Reciprocal control of T helper cell and dendritic cell differentiation. Science 283:1183, 1999.
86. Gilliet M, Liu YJ: Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells. J Exp Med 195:695, 2002.
87. Jahnsen FL, Lund-Johansen F, Dunne JF, Farkas L, Haye R, Brandtzaeg P: Experimentally induced recruitment of plasmacytoid (CD123high) dendritic cells in human nasal allergy. J Immunol 165:4062, 2000.
88. Luft T, Pang KC, Thomas E, Hertzog P, Hart DN, Trapani J, Cebon J: Type I IFNs enhance the terminal differentiation of dendritic cells. J Immunol 161:1947, 1998.
89. Santini SM, Lapenta C, Logozzi M, Parlato S, Spada M, Di Pucchio T, Belardelli F: Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J Exp Med 191:1777, 2000.
90. Rönnblom L, Alm GV: A pivotal role for the natural interferon α-producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus. J Exp Med 194:F59, 2001.
91. Rönnblom L, Alm GV: An etiopathogenic role for the type I IFN system in SLE. Trends Immunol 22:427, 2001.
92. Gallucci S, Matzinger P: Danger signals: SOS to the immune system. Curr Opin Immunol 13:114, 2001.
93. Gallucci S, Lolkema M, Matzinger P: Natural adjuvants: Endogenous activators of dendritic cells. Nat Med 5:1249, 1999.
94. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A: ChromatinIgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 416:603, 2002.
95. Penna G, Sozzani S, Adorini L: Cutting edge: Selective usage of chemokine receptors by plasmacytoid dendritic cells. J Immunol 167:1862, 2001.
96. Chehadeh W, Kerr-Conte J, Pattou F, Alm G, Lefebvre J, Wattre P, Hober D: Persistent infection of human pancreatic islets by coxsackievirus B is associated with alpha interferon synthesis in beta cells. J Virol 74:10153, 2000.
97. Huang X, Yuang J, Goddard A, Foulis A, James RF, Lernmark A, Pujol Borrell R, Rabinovitch A, Somoza N, Stewart TA: Interferon expression in the pancreases of patients with type I diabetes. Diabetes 44:658, 1995.
98. Foulis AK, Farquharson MA, Meager A: Immunoreactive alpha-interferon in insulin-secreting beta cells in type 1 diabetes mellitus. Lancet 2:1423, 1987.
99. Huang X, Hultgren B, Dybdal N, Stewart TA: Islet expression of interferon-α precedes diabetes in both the BB rat and streptozotocin-treated mice. Immunity 1:469, 1994.
100. Schmid P, Itin P, Cox D, McMaster GK, Horisberger MA: The type I interferon system is locally activated in psoriatic lesions. J Interferon Res 14:229, 1994.
101. Tezak Z, Hoffman EP, Lutz JL, Fedczyna TO, Stephan D, Bremer EG, Krasnoselska-Riz I, Kumar A, Pachman LM: Gene expression profiling in DQAI*0501+ children with untreated dermatomyositis: A novel model of pathogenesis. J Immunol 168:4154, 2002.
102. Lebon P: Inhibition of herpes simplex virus type 1-induced interferon synthesis by monoclonal antibodies against viral glycoprotein D and by lysosomotropic drugs. J Gen Virol 66:2781, 1985.
103. Chuntharapai A, Lai J, Huang X, Gibbs V, Kim KJ, Presta LG, Stewart TA: Characterization and humanization of a monoclonal antibody that neutralizes human leukocyte interferon: A candidate therapeutic for IDDM and SLE. Cytokine 15:250, 2001.
104. Benizri E, Gugenheim J, Lasfar A, Eid P, Blanchard B, Lallemand C, Tovey MG: Prolonged allograft survival in cynomolgus monkeys treated with a monoclonal antibody to the human type I interferon receptor and low doses of cyclosporine. J Interferon Cytokine Res 18:273, 1998.
105. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH: Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35:630, 1992.